Zevra Therapeutics Inc (ZVRA) extends cash runway into 2027 while navigating revenue impacts and preparing for potential FDA ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ALKS stock, giving a Buy rating on September 26. Uy Ear has given his ...

Experts explain all the reasons why it’s hard to wake up in the morning. Plus they share a few tips to help you improve your ...

a Phase 3 study evaluating LUMRYZ as a potential treatment for idiopathic hypersomnia (IH). "IH is a debilitating sleep disorder characterized by profound sleep inertia, or difficulty waking up ...

By addressing critical unmet medical needs, biotech companies are transforming healthcare with groundbreaking therapies. A ...

The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological ...

Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) at the ...

Anne Marie Morse, DO, director of pediatric neurology and pediatric sleep medicine at Geisinger Janet Weis Children’s Hospital, was recognized with the Patient Advocate Award by the organization Wake ...

We recently compiled a list of the 10 Stocks with Biggest Upside Potential According to Hedge Funds. In this article, we are ...